BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Search i

Search help

  • Enter one or more search terms in the search field. Upper and lower case are not relevant.
  • As soon as you have entered three letters in the search field, various search words will be suggested from which you can choose one.
  • If you are searching for a certain group of words, put these words in double quotes. The hits will then contain the words in the order you entered, e.g. "medicines for children".
  • Multiple search terms can also be combined with the Boolean operators AND and OR. When using the operator AND, the results contain the intersection of all search terms. When using the operator OR, the hits contain one of the search terms or only individual search terms. The result set is therefore significantly larger. Please note that these operators must be written in capital letters.
  • If you receive a (too) large number of hits as a result of your search, you can narrow it down by using filters. These filter options appear to the left of the search results and are subdivided into:

    • category (e.g. safety of medicinal products, medical devices, code systems)
    • format (e.g. download, risk information, DHPCs)
    • time interval (e.g. last 30 days, older than ...)
  • Selected filters can be removed individually or all at once ("Show all results").
  • By default, search results are sorted by relevance, but they can also be sorted chronologically ("Latest entries first" or "Oldest entries first").

Enter search term

447 results

Results per page: 10 20 30

Selected filter

Information Letter on Trobalt® (retigabine): worldwide withdrawal PDF, 103KB, File is accessible Date: 24. April 2017 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: retigabin

The company GlaxoSmithKline GmbH & CO KG is sending out information that as of the end of June 2017, all strengths of the medicinal product Trobalt® (retigabine) will be discontinued on a worldwide level and will thus cease to be …

Information letter on Clexane® (enoxaparin sodium): update of the information on the strength of the medicinal product, as well as on dosage recommendations and recommendations for use PDF, 2MB, File is accessible Date: 13. April 2017 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: enoxaparin sodium

The company Sanofi-Aventis Deutschland GmbH is sending out information that the information on the effective strength of the medicinal product, the dosage recommendation for the treatment of deep vein thrombosis (DVT) and pulmonary embolism …

Dear Doctor Letter (Rote-Hand-Brief) on Fastjekt®/Fastjekt® Junior: recall of individual batches due to possible defects PDF, 297KB, File is accessible Date: 13. April 2017 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: Epinephrin

In coordination with the competent supervisory authority, the regional council ("Regierungspräsidium") in Darmstadt, the company Meda Pharma GmbH & Co. KG has initiated a voluntary recall of the listed batches of the adrenaline …

Renewed information on Erwinase® 10,000 IU/vial (crisantaspase): shortage and instructions for use for further batches 179a* and 180a* PDF, 260KB, File is accessible Date: 12. April 2017 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: crisantaspase

The company Jazz Pharmaceuticals Germany GmbH is circulating information on the fact that, due to a temporary shortage, Erwinase® 10.000 I.U./vial powder for solution for injection is currently only available under consideration of the …

Dantrolen i.v.: packages no longer contains water for injection PDF, 220KB, File is accessible Date: 22. March 2017 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: dantrolene

The company Norgine GmbH is circulating information that as of April 2017 (the 12 vial pack) or May 2017 (the 36 vial pack), packages of Dantrolen i.v. newly placed on the market no longer contain water for injection. Care must be taken that …

Dear Doctor Letter (Rote-Hand-Brief) on Viread® 204 mg film-coated tablet: incorrect dosage information in previous Summaries of Product Characteristics PDF, 242KB, File is accessible Date: 15. March 2017 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: tenofovir disoproxil

The company Gilead Sciences GmbH is circulating information on incorrect dosage information in the Summaries of Product Characteristics of Viread 204 mg film-coated tablets.

Dear Doctor Letter (Rote-Hand-Brief) on Viridal® 40 µg powder and solvent for injection: recall due to membrane defects PDF, 1MB, File is accessible Date: 06. March 2017 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: Alprostadil

The company UCB Pharma GmbH is circulating information on a voluntary recall of the medicinal product Viridal® due to defective membranes of the glass cartridges.

Information Letter on Erwinase® 10.000 IU/vial, powder for solution for injection: information on temporary shortage PDF, 261KB, File is accessible Date: 31. January 2017 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: crisantaspase

The company Jazz Pharmaceuticals Germany GmbH is circulating information on the fact that, due to a temporary shortage, Erwinase® 10.000 I.U./vial powder for solution for injection is currently only available under consideration of the …

Information Letter on Kyprolis® 30 mg vial (carfilzomib): Recall due to possible cracks in the glass of the vials PDF, 29KB, File is accessible Date: 21. December 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: carfilzomib

The company Amgen is circulating information on a voluntary recall of the medicinal product Kyprolis® 30 mg vial.

Information letter on Ammonaps® (sodium phenylbutyrate) tablets and granules: Treatment only if no alternative is available
PDF, 422KB, File is accessible
Date: 13. December 2016 Topics: Pharmakovigilanz Type: Direct Healthcare Professional Communication

Active substance: sodium phenylbutyrate

In view of failings found in the manufacturing site of Ammonaps® (sodium phenylbutyrate) the company Swedish Orphan Biovitrum International AB (Sobi) is circulating information on temporary precautionary measures regarding treatment with …